RESULTS	Median time to pain progression was not yet reached in the enzalutamide group ( 95 % CI not yet reached to not yet reached ) versus 138 ( 138 to not yet reached ) months in the placebo group ( HR 056 [ 95 % CI 041 to 078 ] ; p = 00004 ) .\